Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | ADRB3 | P13945 | 8/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4467885 | 1.00 | ADRB2 (0.73) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL9543386 | 1.00 | ADRB2 (0.73) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL9467104 | 0.95 | ADRB2 (0.68) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL11467407 | 0.91 | ADRB2 (0.61) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL11467406 | 0.91 | ADRB2 (0.61) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL10720145 | 0.90 | ADRB2 (0.77) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| Bromide SCHEMBL11470044 | 0.89 | ADRB2 (0.59) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| Bromide SCHEMBL11470045 | 0.89 | ADRB2 (0.59) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL19245594 | 0.86 | ADRB2 (0.71) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL19245591 | 0.86 | ADRB2 (0.71) | ADRB2KDM4EGAASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101516826-B | Beta-3 receptor ligands | UNIV BARI | 2015-03-04 | — | — | CN | claimed |
| CN-101516826-B | Beta-3 receptor ligands | UNIV BARI | 2015-03-04 | — | — | CN | disclosed |
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| CN-101516826-A | Beta-3 receptor ligands and therapeutic uses thereof | UNIV BARI (IT) | 2009-08-26 | — | — | CN | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| EP-1546086-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
| WO-2004002939-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | ADRB2 40/4885KDM4E 2289/4885GAA 3421/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | ADRB2 123/4885KDM4E 1554/4885GAA 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.